Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients.
We evaluate the effect of a standardized dietary supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.
Derosa
G
G
University of Pavia, Department of Internal Medicine and Therapeutics, P.le C. Golgi, 2 - 27100, Pavia, Italy. giuseppe.derosa@unipv.it
Maffioli
P
P
D'Angelo
A
A
Salvadeo
S A T
SA
Ferrari
I
I
Fogari
E
E
Gravina
A
A
Mereu
R
R
Randazzo
S
S
Cicero
A F G
AF
D016022:Case-Control Studies; D050171:Dyslipidemias / Q000188:drug therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D045726:Metalloproteases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010919:Placebos; D011480:Protease Inhibitors / Q000627:therapeutic use*
D015525:Fatty Acids, Omega-3; D010919:Placebos; D011480:Protease Inhibitors; D045726:Metalloproteases